The Latest Breaking News from LLY

Despite the cooling inflation, the Fed is not expected to cut rates in 2023 as it is committed to achieving its 2% inflation target. Continued rate hikes, albeit at a lower rate, could potentially push the economy into a recession this year. Amid lingering recession fears, it could be wise…

Pharma sector usually performs relatively well amid market turmoil due to the inelastic demand for its offerings. Moreover, increased technological advancements should boost the industry’s growth. Hence, pharma stocks Eli Lilly (LLY), AstraZeneca (AZN), Zoetis (ZTS), and Teva Pharmaceutical (TEVA) might be worth buying in 2023. Read more.

The pharmaceutical industry is rapidly evolving to meet today’s health challenges. The pharmaceutical industry's long-term prospects look bright with a globally aging population set to increase healthcare expenditure. Moreover, given the industry’s ability to stay resilient amid economic headwinds, it could be wise to invest in fundamentally strong pharmaceutical stocks…

Editor's note: This story has been corrected to reflect that the FDA deferred action on Amicus Therapeutics' Biologics License Application. 

Although the stock market has been under pressure this year due to macroeconomic headwinds, the pharmaceutical industry continues to garner investor attention as it enjoys inelastic demand for its products regardless of economic conditions. Thus, fundamentally-sound pharma stocks Eli Lilly (LLY) and Bristol-Myers Squibb (BMY) could be worth your attention…

A whale with a lot of money to spend has taken a noticeably bearish stance on Eli Lilly. Looking at options history for Eli Lilly (NYSE:LLY) we detected 21 strange trades.

Someone with a lot of money to spend has taken a bullish stance on Eli Lilly (NYSE:LLY). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Despite the Fed’s continued hawkish stance, the September inflation report came in hotter than expected, raising the possibility of another aggressive interest rate hike in November. However, it could be smart to keep investing in quality stocks to benefit from their rebound. We think Microsoft (MSFT), Eli Lilly (LLY), and…

A whale with a lot of money to spend has taken a noticeably bearish stance on Eli Lilly. Looking at options history for Eli Lilly (NYSE:LLY) we detected 10 strange trades.